Insulins

However, he added that, in his personal view, the decision by Novo Nordisk to remove some of its modern insulins from the Greek market following price cuts there was not necessarily helpful to the debate. ❋ Unknown (2010)

I don't have to worry about what Lantus or other long term insulins are doing to me if I don't get to eat when it peaks, because it offers a constant supply of Humalog to my system. ❋ Unknown (2010)

How do you see how you can gain market share against Novo given that they are launching their own GLP-1 in probably two years before yours, and also have a next generation wave of insulins, which is probably three or four years ahead of yours? ❋ Unknown (2010)

Even among insulin now, we have different kind of insulins -- ones that last a long time, a whole day; ones that last very shortly. ❋ Unknown (2005)

When cash-strapped Greece last year told Danish drug maker Novo Nordisk A/S it planned to cut the prices it paid for certain insulins by more than a quarter in an effort to slash its spending, Lars Rebien Sorensen , the company's chief executive, responded by halting deliveries of the products. ❋ Jeanne Whalen (2011)

There are also growing pressures in some Western markets to keep patients on older, cheaper forms of medication, which cuts against the company's strategy of converting diabetics to more modern insulins, he says. ❋ Jeanne Whalen (2011)

The product is designed to control blood-sugar levels over a longer period of time than other insulins do, though if it is approved for sale it will face tough competition from products made by Sanofi SA and Eli Lilly & Co . ❋ Jeanne Whalen (2011)

"Biocon will enable Pfizer to have a first-mover advantage in this very large and emerging market opportunity that lies in biosimilar insulins," Kiran Mazumdar-Shaw, chairman and managing director of Biocon, told reporters in a conference call Monday. ❋ Rumman Ahmed (2010)

Amid the rapid spread of diabetes, Novo Nordisk's earnings have grown steadily, driven by rising sales of treatments for the disease like insulins as well as the recently-launched Victoza, which belongs to the GLP-1 analogue drug class and compared with insulin doesn't risk pushing blood sugar too low. ❋ Gustav Sandstrom (2010)

Growth in 2011 will be helped by strong penetration of modern insulins and continued roll-out of new diabetes treatment Victoza, Novo Nordisk said. ❋ Gustav Sandstrom (2010)

"Growth was driven by the modern insulins, Victoza and NovoSeven, and with North America and international operations representing the majority of the growth from a geographic perspective," the company said. ❋ Gustav Sandstrom (2010)

"We will see when we come to market with this next generation of modern insulins, the pricing will probably be such that patients in Northern Europe may have more of a chance to get these products than patients in Southern Europe because health authorities…will not reimburse them." ❋ Jeanne Whalen (2011)

Injectable insulins, medications like aspirin, and diabetes pills accounted for another third of the hospitalizations. ❋ Timothy W. Martin (2011)

With Monday's price level, the price for a daily treatment of Novo Nordisk's best insulins would be some ❋ Unknown (2010)

Its sales of modern insulins -- versions of human insulins which have been modified for greater effect -- have been particularly strong, growing 17% year-to-year in the first quarter to 5.86 billion kroner. ❋ Unknown (2010)

A/S said Monday it has decided to resume sales of modern insulins in Greece after authorities there raised prices of these products to an "acceptable" level, albeit not as high as the Danish pharmaceutical company would have liked. ❋ Unknown (2010)

We approved the insulins in record time: five months. ❋ MD Henry Miller (2010)

Drug Administration's review of the first genetically engineered biopharmaceuticals human insulins produced in bacteria that are now used by millions of diabetics. ❋ MD Henry Miller (2010)